According to this post from Life Sci VC, corporate Venture Capital groups are now essential to the biotech ecosystem and provide the bulk of capital to fudn new companies -- at least from Atlas Funds point of view -- which appears to be a representative one indeed.
From Atlas data, corporate VC had only 5% involvement in their projects from 2000-2005, that rose to 33% from 2006-2008 and now stands at a whopping 67% from 2009-present. What's more? The funds range in size from $100 M - $500 M and account for at least $2.5 B in VC money, according to author's estimates.
That's a lot of money. Money that new companies in biotech are increasingly dependent upon. An Xconomy underscores this today with a piece on the dearth of cash available to biotechs from traditional VC sources. Have a read. Clearly the availability of more money is needed to get these new biotech ventures off the ground to take advantage of innovative science.
Posted by Bruce Lehr Jan 23rd 2012
Comments